We’d love to hear your feedback on this activity. It helps us to continually improve our products.
We had the pleasure of meeting with Yona Levites (Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA) to discuss immunotherapeutic approaches in Alzheimer’s Disease. Part 2 of the discussion can be viewed here. The abstract entitled ‘Immunotherapeutic approaches in Alzheimer’s Disease’ was presented at The 15th International Conference for Alzheimer’s […]
We had the pleasure of meeting with Yona Levites (Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA ) to discuss her phase 1 study investigating the scFv-CD protein as a framework for identifying an optimized immunotherapy for Alzheimer’s Disease, and potentially other neurodegenerative disorders. Part 1 of the discussion can […]
touchNEUROLOGY had the pleasure of meeting with Tobias Hartmann (Director and Professor of Experimental Neurology, DIDP, Saarland University, Saarbrücken, Germany) to discuss the recent post-hoc analysis of the LipiDiDiet trial data. Part 1 of our discussion can be found here. The abstract entitled ‘ADCOMS: A Post-Hoc Analysis Using Data from the 3-Year Lipididiet Trial in […]
We had the great pleasure of meeting with Tobias Hartmann (Director and Professor of Experimental Neurology, DIDP, Saarland University, Saarbrücken, Germany) to discuss the diet and nutritional interventions in the progress from MCI to dementia. Part 2 of our discussion can be found here. The abstract entitled ‘ADCOMS: A Post-Hoc Analysis Using Data from the […]
touchNEUROLOGY had the pleasure of meeting with Andrew Feigin (Department of Neurology, NYU Grossman School of Medicine, New York City, NY, USA) and Ralf Reilmann (Founding Director, George Huntington Institute, Münster, Germany), to discuss the clinical utility of pridopidine in Huntington’s disease, and the ongoing PROOF-HD study. The abstract entitled ‘The PROOF-HD Study: Pridopidine’s Outcome […]
We had the opportunity to meet with Andrew Feigin (Department of Neurology, NYU Grossman School of Medicine, New York City, NY, USA) to discuss the results from the phase 2 Huntington’s Disease trial of Anti-Semaphorin 4D Antibody Pepinemab (SIGNAL). The abstract entitled ‘Results of Phase 2 Huntington’s Disease Trial of Anti-Semaphorin 4D Antibody Pepinemab (SIGNAL) […]
It was a pleasure to talk to Pat Penovich (Minnesota Epilepsy Group, St. Paul, MN, USA) about the exit survey, of a Phase 3 study, assessing patient experience of using the diazepam nasal spray for seizure clusters. The abstract ‘Examining the Patient Experience With Diazepam Nasal Spray for Seizure Clusters: Patient-reported Results From an Exit […]
touchNEUROLOGY were delighted to have the opportunity to speak with Amos Korczyn, Founder and President of CONy about his highlights of this year’s virtual meeting. Questions What were your personal highlights of CONy 2020? (0:05) Tell us about plans for CONy 2021 (4:43) Support: Interview and filming supported by Touch Medical Media Ltd. Disclosures: Founder […]
It was a pleasure to speak with Martin Brodie (President, International Bureau for Epilepsy and co-Section Head of Epilepsy for CONy), who spoke with us on the topic of the debate session he participated in: Should combination antiepileptic drug (AED) therapy be offered immediately after failure of a single antiepileptic drug? Questions Could you tell […]
Get the latest clinical insights from touchNEUROLOGY